The FDA has approved Spravato (esketamine, Janssen) for treatment of treatment-resistant depression in adults. It is a nasal spray that must be used in conjunction with an oral antidepressant in a certified physician's office or clinic. Esketamine is the s-enantiomer of ketamine.
The patient self-administers the esketamine spray under supervision, with treatments twice a week for four weeks.
AR Psychiatric And Counseling Center is a certified SPRAVATO™ treatment center as defined as having submitted evidence of completed patient monitoring as part of the SPRAVATO™ REMS patient registry